Talphera Inc (TLPH)

Currency in USD
0.7865
+0.0004(+0.05%)
Real-time Data·
TLPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.77850.8100
52 wk Range
0.38001.5700
Key Statistics
Prev. Close
0.7861
Open
0.7851
Day's Range
0.7785-0.81
52 wk Range
0.38-1.57
Volume
84.74K
Average Volume (3m)
198.38K
1-Year Change
56.9302%
Book Value / Share
0.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TLPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.2500
Upside
+313.22%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Talphera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Buy
Moving Averages
Strong Sell

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Employees
12

Talphera Inc Earnings Call Summary for Q4/2025

  • Talphera stock fell 6.24% to $0.8003 in premarket trading, down 26.94% year-to-date, following Q4 earnings call and study delay concerns.
  • Nephro CRRT study reached 50% enrollment but completion delayed to second half of 2026, pushing FDA approval timeline to late 2026 or early 2027.
  • Company maintains strong liquidity with $20.4M cash and investments plus $4.1M additional financing, sufficient through anticipated FDA approval.
  • Management shifted to nephrology-led study sites to accelerate enrollment; PMA submission planned shortly after study completion in H2 2026.
  • Analysts maintain bullish outlook with price targets of $3.00-$3.50, suggesting significant upside despite pre-commercial status and revenue absence.
Last Updated: 2026-03-23, 12:54 p/m
Read Full Transcript

Compare TLPH to Peers and Sector

Metrics to compare
TLPH
Peers
Sector
Relationship
P/E Ratio
−2.8x−8.3x−0.5x
PEG Ratio
−0.080.010.00
Price/Book
2.4x4.3x2.6x
Price / LTM Sales
1,436.8x28.3x3.2x
Upside (Analyst Target)
313.4%127.4%45.2%
Fair Value Upside
Unlock2.2%6.4%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.2500
(+313.22% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 23, 2026
EPS / Forecast
-0.06 / -0.16
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TLPH Income Statement

People Also Watch

0.189
ERNA
-2.48%
1.370
QNCX
0.00%
1.190
NUWE
+2.59%
2.2000
GLBS
+5.26%
3.9700
ARTL
-0.75%

FAQ

What Is the Talphera (TLPH) Stock Price Today?

The Talphera stock price today is 0.7865 USD.

What Stock Exchange Does Talphera Trade On?

Talphera is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Talphera?

The stock symbol for Talphera is "TLPH."

What Is the Talphera Market Cap?

As of today, Talphera market cap is 39.3400M USD.

What Is Talphera's Earnings Per Share (TTM)?

The Talphera EPS (TTM) is -0.3387.

From a Technical Analysis Perspective, Is TLPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Talphera Stock Split?

Talphera has split 1 times.

How Many Employees Does Talphera Have?

Talphera has 12 employees.

What is the current trading status of Talphera (TLPH)?

As of Apr 23, 2026, Talphera (TLPH) is trading at a price of 0.7865 USD, with a previous close of 0.7861 USD. The stock has fluctuated within a day range of 0.7785 USD to 0.8100 USD, while its 52-week range spans from 0.3800 USD to 1.5700 USD.

What Is Talphera (TLPH) Price Target According to Analysts?

The average 12-month price target for Talphera is 3.2500 USD, with a high estimate of 3.5 USD and a low estimate of 3 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +313.22% Upside potential.

What Is the TLPH Premarket Price?

TLPH's last pre-market stock price is 0.8299 USD. The pre-market share volume is 110.0000, and the stock has decreased by 0.0438, or 5.5700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.